Physician profile
Matthew Chan
NPI 1770077349
$2,241.76
in general payments reported to CMS, 2019-2025
23 companies · $979 in 2025
The $979 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2022: $45.26 · 2023: $492 · 2024: $591 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,061.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $819.38 | 2022-2025 | Skyrizi |
| Medtronic, INC. | $152.85 | 2023 | Barrx |
| E.R. Squibb & Sons, L.L.C. | $145.25 | 2023 | Zeposia |
| Astrazeneca Pharmaceuticals Lp | $134.66 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.80 | 2022-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $97.57 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $93.74 | 2024-2025 | Tremfya, Stelara |
| Pfizer INC. | $89.27 | 2025 | |
| Laborie Medical Technologies Corp. | $58.68 | 2024-2025 | |
| Genzyme Corporation | $56.38 | 2024-2025 | |
| Gilead Sciences, INC. | $51.77 | 2025 | |
| Novo Nordisk INC | $51.37 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $50.33 | 2023-2024 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $44.21 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $42.38 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $41.00 | 2025 | Zenpep |
| Lilly USA, LLC | $36.96 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $34.56 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $34.32 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $33.81 | 2023 | Spyglass, Extractor Pro Rx |
| Daiichi Sankyo INC. | $24.97 | 2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $22.34 | 2024 | |
| Exact Sciences Corporation | $16.16 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.